Vanguard Group
VIVO

Vanguard Group’s Meridian Bioscience Inc VIVO Stock Holding History

Vanguard Group’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,970,105
Closed -$165M – 4640
2022
Q4 		$165M Buy
4,970,105
+41,857
+0.8% +$1.35M ﹤0.01% 1536
2022
Q3 		$155M Buy
4,928,248
+24,198
+0.5% +$784K ﹤0.01% 1536
2022
Q2 		$149M Buy
4,904,050
+112,548
+2% +$3.04M ﹤0.01% 1592
2022
Q1 		$124M Sell
4,791,502
-85,440
-2% -$2.03M ﹤0.01% 1821
2021
Q4 		$99.5M Sell
4,876,942
-126,680
-3% -$2.43M ﹤0.01% 1986
2021
Q3 		$96.3M Sell
5,003,622
-71,162
-1% -$1.42M ﹤0.01% 2003
2021
Q2 		$113M Buy
5,074,784
+23,487
+0.5% +$498K ﹤0.01% 1940
2021
Q1 		$133M Buy
5,051,297
+293,582
+6% +$6.98M ﹤0.01% 1803
2020
Q4 		$88.9M Buy
4,757,715
+105,558
+2% +$1.97M ﹤0.01% 1889
2020
Q3 		$79M Buy
4,652,157
+90,046
+2% +$1.75M ﹤0.01% 1802
2020
Q2 		$106M Buy
4,562,111
+262,340
+6% +$3.8M ﹤0.01% 1649
2020
Q1 		$36.1M Sell
4,299,771
-302,055
-7% -$2.54M ﹤0.01% 2014
2019
Q4 		$45M Buy
4,601,826
+201,408
+5% +$1.89M ﹤0.01% 2166
2019
Q3 		$41.8M Sell
4,400,418
-167,796
-4% -$1.77M ﹤0.01% 2154
2019
Q2 		$54.3M Buy
4,568,214
+8,459
+0.2% +$102K ﹤0.01% 2062
2019
Q1 		$80.3M Buy
4,559,755
+145,216
+3% +$2.42M ﹤0.01% 1852
2018
Q4 		$76.6M Buy
4,414,539
+66,580
+2% +$1.14M ﹤0.01% 1815
2018
Q3 		$64.8M Buy
4,347,959
+94,180
+2% +$1.46M ﹤0.01% 2016
2018
Q2 		$67.6M Buy
4,253,779
+60,434
+1% +$901K ﹤0.01% 1972
2018
Q1 		$59.5M Sell
4,193,345
-10,983
-0.3% -$163K ﹤0.01% 1987
2017
Q4 		$58.9M Buy
4,204,328
+162,058
+4% +$2.37M ﹤0.01% 1984
2017
Q3 		$57.8M Buy
4,042,270
+23,285
+0.6% +$333K ﹤0.01% 1967
2017
Q2 		$63.3M Buy
4,018,985
+334,480
+9% +$4.82M ﹤0.01% 1901
2017
Q1 		$50.8M Buy
3,684,505
+70,081
+2% +$980K ﹤0.01% 2002
2016
Q4 		$64M Buy
3,614,424
+31,905
+0.9% +$560K ﹤0.01% 1855
2016
Q3 		$69.1M Buy
3,582,519
+165,216
+5% +$3.23M ﹤0.01% 1780
2016
Q2 		$66.6M Buy
3,417,303
+171,772
+5% +$3.37M ﹤0.01% 1768
2016
Q1 		$66.9M Buy
3,245,531
+80,432
+3% +$1.58M ﹤0.01% 1721
2015
Q4 		$64.9M Buy
3,165,099
+79,147
+3% +$1.52M ﹤0.01% 1759
2015
Q3 		$52.8M Buy
3,085,952
+73,481
+2% +$1.34M ﹤0.01% 1840
2015
Q2 		$56.2M Buy
3,012,471
+73,677
+3% +$1.37M ﹤0.01% 1874
2015
Q1 		$56.1M Buy
2,938,794
+233,838
+9% +$4.32M ﹤0.01% 1850
2014
Q4 		$44.5M Sell
2,704,956
-140,401
-5% -$2.41M ﹤0.01% 1890
2014
Q3 		$50.3M Buy
2,845,357
+47,734
+2% +$938K ﹤0.01% 1785
2014
Q2 		$57.7M Buy
2,797,623
+77,806
+3% +$1.6M ﹤0.01% 1753
2014
Q1 		$59.3M Sell
2,719,817
-94,301
-3% -$2.16M 0.01% 1711
2013
Q4 		$74.7M Sell
2,814,118
-8,824
-0.3% -$217K 0.01% 1516
2013
Q3 		$66.8M Buy
2,822,942
+293,903
+12% +$6.86M 0.01% 1532
2013
Q2 		$54.4M Buy
+2,529,039
New +$54.5M 0.01% 1581

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Vanguard Group's VIVO Position: Q1 2023 in Review

Vanguard Group sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 4,970,105 shares — an estimated $165M sold.

Vanguard Group first reported a position in VIVO in Q2 2013 and held it in 39 quarters. The position peaked at $165M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Vanguard Group reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Vanguard Group sold 4,970,105 Meridian Bioscience Inc shares in Q1 2023, an estimated $165M.
  • Vanguard Group first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 39 quarters.
  • Vanguard Group's Meridian Bioscience Inc position peaked at $165M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.